FDA's Lab-Developed Test Rule Is Dead, But the Debate It Started Isn't

Introduction

For about a year, diagnostics companies and the regulatory affairs teams that serve them worked under the assumption that laboratory developed tests, or LDTs, were headed toward full FDA device regulation. Then a federal court took that assumption off the table. The story of what happened — a final rule issued, challenged, and then vacated — is worth understanding in detail, because the underlying question it raised has not gone away, and the regulatory affairs work it generated did not disappear either.

An LDT is an in vitro diagnostic test that is designed, manufactured, and used within a single laboratory, rather than sold as a packaged kit to other labs. Historically, FDA treated most LDTs under a policy of enforcement discretion: it had the legal authority to regulate them as medical devices but generally chose not to exercise it, leaving oversight mostly to the Centers for Medicare and Medicaid Services through the Clinical Laboratory Improvement Amendments, or CLIA, which governs laboratory quality systems rather than individual test design or clinical validity.

What the 2024 Final Rule Tried to Do

In the spring of 2024, FDA finalized a rule intended to phase out that enforcement discretion approach. The rule did not create a new legal category for LDTs; instead, it clarified that LDTs fall within the existing statutory definition of a medical device and laid out a multi-stage phaseout, stretched across several years, during which FDA would progressively start enforcing device requirements that had previously been waived in practice — adverse event reporting, registration and listing, quality system requirements, and ultimately premarket review for higher-risk tests.

For regulatory affairs teams at academic medical centers, reference laboratories, and diagnostics companies that ran their own LDT menus, the rule meant real work: gap assessments against design control requirements, decisions about which tests would need 510(k) or De Novo submissions, and budget conversations about building out quality management systems that many labs had never needed under CLIA alone.

Why a Federal Court Vacated It

The rule was challenged almost immediately. The American Clinical Laboratory Association and the Association for Molecular Pathology sued FDA, arguing that the agency had exceeded the authority Congress gave it. Their central argument was a familiar one in administrative law: LDTs are professional laboratory services, not manufactured products shipped in commerce, and Congress never clearly authorized FDA to regulate them as devices through this route. They also argued that decades of a different legislative framework specific to laboratories, CLIA, showed Congress intended a different regulator to own this space.

In early 2025, a federal district court in Texas agreed, vacating the rule nationwide. The court's reasoning tracked the plaintiffs' core argument: that FDA had stretched the statutory definition of a device further than the text and legislative history supported, and that an agency cannot claim sweeping new authority over an entire category of medical practice through a single rulemaking without clearer direction from Congress. Because the vacatur was nationwide rather than limited to the plaintiff associations, it effectively reset LDT oversight back to where it stood before the rule was finalized.

A Longer Fight Than One Rule

The 2024 rule wasn't FDA's first attempt to settle this question, and the vacatur is unlikely to be the last word either. For years before the rule, members of Congress introduced versions of legislation often referred to as the VALID Act, intended to create a unified regulatory framework for in vitro clinical tests that would have covered LDTs alongside traditional test kits, with risk-based tiers and a technology certification pathway for high-volume labs. That legislation was reintroduced repeatedly but never passed, in part because laboratory groups and diagnostics manufacturers disagreed sharply on how it should work, and in part because competing legislative priorities kept crowding it out. When legislative efforts stalled, FDA eventually moved to try the rulemaking route instead, arguing it already had the statutory authority it needed without waiting for Congress. The court's vacatur is, in a sense, a rejection of that shortcut rather than a final verdict on whether any federal LDT oversight beyond CLIA is appropriate at all.

That history matters for anyone trying to predict what comes next. A legislative fix would look different from a narrower rule: it could carve out explicit exemptions for certain categories of labs, such as academic medical centers running tests for their own patients, that the 2024 rule treated similarly to commercial laboratories. A revised rule, by contrast, would have to work within the existing statutory definition of a device and would face the same basic legal vulnerability that sank the first attempt unless Congress acts first.

What Changed, and What Didn't, on the Ground

The immediate legal effect was straightforward: FDA's phaseout timeline stopped, and the enforcement discretion policy that predated the 2024 rule is, for now, back in force. Labs are not required to register, list, or submit premarket applications for LDTs because of that rule, since the rule no longer exists.

What didn't change is less visible but matters more for people building careers in this space. Many diagnostics companies and health systems had already begun compliance work before the vacatur — gap assessments, early design history file construction, hiring to build out regulatory and quality functions that hadn't previously needed device-level rigor. Pulling that investment back out is its own decision, and plenty of organizations have chosen to keep some or most of it in place, reasoning that another rulemaking attempt, new legislation, or simply market expectations from payers and health systems could require the same capabilities again. A compliance program built once is cheaper to maintain than to rebuild from nothing a second time.

It's also worth noting that CLIA oversight never went away. Labs still have to meet CLIA's quality requirements, undergo inspections, and in some states meet additional state-specific requirements. New York, for instance, has long required its own separate approval process for LDTs offered to New York patients, regardless of what FDA does federally, and that state-level layer is unaffected by the vacatur.

Why This Still Matters for Regulatory Affairs Hiring

It would be easy to read "the rule was vacated" as "the regulatory work disappeared," but that's not quite what's happening in hiring. A few things are keeping LDT-adjacent regulatory affairs roles active even without the rule in force.

First, the underlying policy question is unresolved, not settled. FDA could appeal, could attempt a narrower rulemaking that tries to avoid the court's specific objections, or Congress could take up legislation that has circulated in various forms for years and would give FDA explicit statutory authority over at least some categories of diagnostic tests. Any of those paths would restart timeline pressure, and companies that let their compliance infrastructure lapse entirely would be starting from behind.

Second, large reference laboratories and diagnostics companies that sell across state lines, or that want their tests reimbursed by payers who increasingly ask about analytical and clinical validation regardless of what FDA strictly requires, have business reasons to maintain device-like rigor that have nothing to do with the vacated rule. Regulatory affairs professionals who can speak both CLIA laboratory quality language and FDA device submission language remain genuinely useful, rule or no rule.

Third, companies that build combination diagnostic-therapeutic products, companion diagnostics tied to a specific drug label, or home-use and point-of-care tests were generally always squarely within FDA's device jurisdiction regardless of the LDT enforcement discretion question, so hiring in those adjacent categories hasn't been affected by the litigation at all.

What to Watch For Next

If you work in or are targeting diagnostics regulatory affairs, a few signals are worth tracking. Watch whether FDA appeals the vacatur or lets it stand. Watch whether Congress revisits legislation that would give FDA clearer statutory authority over LDTs, since that path would sidestep the court's objection to how the 2024 rule was built rather than whether Congress could authorize something similar through ordinary legislation. And watch what large health systems and reference labs actually do with the compliance infrastructure many of them had already started building, since that practical choice will tell you more about near-term hiring demand than the legal status of the rule itself.

In the meantime, the skill set this episode rewards is less about memorizing a specific rule's requirements and more about tracking regulatory and legislative developments closely enough to advise a company on risk even when the legal landscape is actively shifting underneath it. That's a genuinely valuable capability in diagnostics regulatory affairs, and it doesn't depend on any single rule staying in force.

For job seekers, this is also a reminder to read job postings in this space carefully. A posting that lists "LDT compliance" or "device-style quality system build-out" as a core responsibility may reflect a company's own risk calculus rather than a current legal mandate, and that's worth asking about directly in an interview. Understanding why a company has chosen to keep investing in this area, even without a rule requiring it, tells you a lot about how seriously they take regulatory risk more broadly, and that's usually a good proxy for how the role itself will be resourced.

Conclusion

The 2024 LDT rule's short life and vacatur is a useful case study in how quickly the regulatory ground can move, and how little that movement sometimes changes about what regulatory affairs professionals are actually asked to do day to day. The rule is gone, but the question it tried to answer — who should set the bar for a test built and used entirely within one laboratory — is still open, and companies with diagnostics in their pipeline are still hiring people who can navigate that uncertainty rather than wait for it to resolve.